Tetralogic Pharmaceuticals Corp (TLOG) & The Competition Head-To-Head Contrast

Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Tetralogic Pharmaceuticals Corp to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, earnings, analyst recommendations and profitability.

Profitability

This table compares Tetralogic Pharmaceuticals Corp and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%
Tetralogic Pharmaceuticals Corp Competitors -910.58% -183.99% -27.07%

Valuation and Earnings

This table compares Tetralogic Pharmaceuticals Corp and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Tetralogic Pharmaceuticals Corp N/A -$21.14 million -0.03
Tetralogic Pharmaceuticals Corp Competitors $224.58 million $57.96 million -1.18

Tetralogic Pharmaceuticals Corp’s competitors have higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. Comparatively, 20.3% of shares of all “Biotechnology” companies are owned by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Tetralogic Pharmaceuticals Corp and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A
Tetralogic Pharmaceuticals Corp Competitors 123 467 1168 11 2.60

As a group, “Biotechnology” companies have a potential upside of 69.24%. Given Tetralogic Pharmaceuticals Corp’s competitors higher probable upside, analysts plainly believe Tetralogic Pharmaceuticals Corp has less favorable growth aspects than its competitors.

Volatility & Risk

Tetralogic Pharmaceuticals Corp has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp’s competitors have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.

Summary

Tetralogic Pharmaceuticals Corp competitors beat Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared.

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply